Abstract
Oxidative stress is often considered as a causative factor in carcinogenesis. In addition, current knowledge recognizes oxidative stress as a mechanism by which various cancer therapies act against cancer. To ameliorate the side effects of cancer therapy, many of the patients suffering from cancer are subject to adjuvant therapy, which often implies antioxidant supplementation. Yet, the benefits of such adjuvant treatments are still uncertain owing to the lack of appropriate integrative and personalized medical approach. In particular, reactive oxygen species formed during oxidative stress and products of lipid peroxidation are not only cytotoxic, but can modulate signal transduction in cells, which also behave similar to individuals under stress. Accordingly, pro-oxidants and antioxidants might be considered as modifiers of specific cellular redox signaling. Therefore, there is a need to evaluate the potential benefits of antioxidant supplements in healthy persons, and in particular in cancer patients during therapy. Our review will present a summary of the existing knowledge regarding the effects of various antioxidants in cancer therapies, focusing on cellular adaptation to oxidative stress interacting with redox signaling transduction pathways thereby influencing cell growth.
Keywords: Oxidative stress, reactive oxygen species (ROS), lipid peroxidation, carcinogenesis, redox signaling, anoikis, antioxidants, therapy.
Current Pharmaceutical Design
Title:Oxidative Stress and Antioxidants in Carcinogenesis and Integrative Therapy of Cancer
Volume: 20 Issue: 42
Author(s): Lidija Milkovic, Werner Siems, Renate Siems and Neven Zarkovic
Affiliation:
Keywords: Oxidative stress, reactive oxygen species (ROS), lipid peroxidation, carcinogenesis, redox signaling, anoikis, antioxidants, therapy.
Abstract: Oxidative stress is often considered as a causative factor in carcinogenesis. In addition, current knowledge recognizes oxidative stress as a mechanism by which various cancer therapies act against cancer. To ameliorate the side effects of cancer therapy, many of the patients suffering from cancer are subject to adjuvant therapy, which often implies antioxidant supplementation. Yet, the benefits of such adjuvant treatments are still uncertain owing to the lack of appropriate integrative and personalized medical approach. In particular, reactive oxygen species formed during oxidative stress and products of lipid peroxidation are not only cytotoxic, but can modulate signal transduction in cells, which also behave similar to individuals under stress. Accordingly, pro-oxidants and antioxidants might be considered as modifiers of specific cellular redox signaling. Therefore, there is a need to evaluate the potential benefits of antioxidant supplements in healthy persons, and in particular in cancer patients during therapy. Our review will present a summary of the existing knowledge regarding the effects of various antioxidants in cancer therapies, focusing on cellular adaptation to oxidative stress interacting with redox signaling transduction pathways thereby influencing cell growth.
Export Options
About this article
Cite this article as:
Milkovic Lidija, Siems Werner, Siems Renate and Zarkovic Neven, Oxidative Stress and Antioxidants in Carcinogenesis and Integrative Therapy of Cancer, Current Pharmaceutical Design 2014; 20 (42) . https://dx.doi.org/10.2174/1381612820666140826152822
DOI https://dx.doi.org/10.2174/1381612820666140826152822 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Liposomes for Enhanced Cellular Uptake of Anticancer Agents
Current Drug Delivery Overcoming Resistance of Glioblastoma to Conventional Cytotoxic Therapies by the Addition of PARP Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Ricin and Saporin: Plant Enzymes for the Research and the Clinics
Current Chemical Biology Molecular Diagnosis in Autoimmune Skin Blistering Conditions
Current Molecular Medicine Status Quo in Antibody-Drug Conjugates - Can Glyco- Enzymes Solve the Current Challenges?
Protein & Peptide Letters Statins and Cancer
Anti-Cancer Agents in Medicinal Chemistry Extracellular Matrix Scaffolds for Tissue Engineering and Regenerative Medicine
Current Stem Cell Research & Therapy Dendritic Cells and their Receptors in Antitumor Immune Response
Current Molecular Medicine Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies
Current Cancer Drug Targets Oxidative DNA Damage and Oxidant/Anti-Oxidant Enzymatic Systems in Carcinogenesis and Cancer Progression
Current Enzyme Inhibition Protein Kinase C as a Drug Target Implications for Drug or Diet Prevention and Treatment of Cancer
Current Drug Targets Editorial [Hot Topic: SOD Enzymes and Their Mimics in Cancer: Pro- vs Anti-Oxidative Mode of Action-Part I (Guest Editor: Ines Batinic-Haberle)]
Anti-Cancer Agents in Medicinal Chemistry Non Steroidal Estrogen Antagonists: Current Status and Future Perspectives
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Nitric Oxide Synthase (NOS) Inhibitors in Cancer Angiogenesis
Current Enzyme Inhibition Protein Kinases and Associated Pathways in Pluripotent State and Lineage Differentiation
Current Stem Cell Research & Therapy Tobacco, Inflammation, and Respiratory Tract Cancer
Current Pharmaceutical Design ras Genes and Human Cancer: Different Implications and Different Roles
Current Genomics Curcumin and Liver Cancer: A Review
Current Pharmaceutical Biotechnology Diversifying Polyhydroxyalkanoates – End-Group and Side-Chain Functionality
Current Organic Synthesis The Role of Neuroendocrine Cells in Prostate Cancer: A Comprehensive Review of Current Literature and Subsequent Rationale to Broaden and Integrate Current Treatment Modalities
Current Medicinal Chemistry